From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q2 2021 call → NOWe need to determine if management describes a recent transition to being an approved/specified/listed/etc. choice inside buyers' systems, such that future business can arrive without discrete selling, and that this is new and most volume is ahead. Scan the transcript. Management discusses strategic imperatives: customer centricity, 365 engagements, portfolio optimization. They mention PlumRiver and ElasticSuite, a digital marketplace with subscription-based revenues. They also mention Sue Bryce Education, a subscription-based platform. They talk about expanding these across brands. But do they say that the company has been placed into a buyer's system (like approved supplier list, formulary, etc.)? They mention "digital marketplace" and "subscription-based" but that's about their own platform, not about being inserted into a buyer's procurement pathway. They also mention "customer data hub" integration, but that's internal. They talk about "365-day tool with recurring subscription-based revenues" - that's a business model, not a status of being an approved vendor in a buyer's system. They don't describe being named to a preferred supplier list, being written into specifications, etc. They mention "new client wins" for ElasticSuite, but that's ordinary selling. The question asks: "has recently crossed from being a candidate that buyers must be persuaded to consider into being an APPROVED, SPECIFIED, LISTED, QUALIFIED, REGISTERED, REIMBURSED, OR PRE-AUTHORIZED choice inside buyers' own purchasing, reimbursement, formulary, specification, procurement, network, catalog, or program systems" - that is a specific phenomenon. The transcript does not mention any such status. They talk about their own platform and subscriptions, but not about being inserted into a buyer's system. They also mention "strategic partnership with Comexposium to launch SIAL America" - that's a new event, not a buyer-side system. Thus, the answer is NO. They don't describe that phenomenon. They describe their own efforts to create recurring revenue, but not that they have been placed into a buyer's procurement pathway. Also, they don't say that most volume is ahead due to that status. So NO. Answer: NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.